TRINETRA › Sectors › Healthcare
IPCA Laboratories Limited (IPCALAB) — share price, P/E and fundamentals
IPCA Laboratories Limited (NSE: IPCALAB) closed at ₹1,927.80 on 30 Oct 2026, +49.9% over one year, against a 52-week range of ₹1,251.60 – ₹2,038.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 13 Aug 2026) it reported revenue of ₹2,788 cr and net profit of ₹402 cr, a 14.4% net margin; revenue grew 20.8% and profit grew 73.1% year on year.
On four consecutive filed quarters its trailing P/E is 37.3; since 29 May 2025 its own P/E has ranged from 33.1 to 54.2 (median 44.5), and today's reading is higher than 11% of those 351 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 19.9%, ROCE 23.2%, debt-to-equity 0.09, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 57% of 63 sector peers; PBT margin higher than 57% of 63 sector peers; ROE higher than 76% of 63 sector peers.
Key figures
| Last close | ₹1,927.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -3.5% / +23.9% / +49.9% |
| 52-week low – high | ₹1,251.60 – ₹2,038.00 |
| Market capitalisation | ₹48,908 cr |
| Trailing P/E | 37.3 |
| Price / book | 6.07 |
| EV / EBITDA | 21.3 |
| Earnings yield | 2.7% |
| TTM EPS | ₹51.63 |
| TTM net profit | ₹1,310 cr |
| Quarter revenue | ₹2,788 cr |
| Quarter net profit | ₹402 cr |
| Net margin | 14.4% |
| Revenue growth (YoY) | +20.8% |
| Profit growth (YoY) | +73.1% |
| Return on equity | 19.9% |
| ROCE | 23.2% |
| Debt / equity | 0.09 |
| Current ratio | 2.76 |
| Free cash flow | ₹490 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹48.3 cr |
Against Healthcare peers
| Metric | IPCALAB | Peer median | Percentile |
|---|---|---|---|
| Net margin | 14.41 | 12.67 | 57 |
| PBT margin | 20.52 | 17.57 | 57 |
| ROE | 19.94 | 13.86 | 76 |
| ROCE | 23.21 | 16.59 | 75 |
| Debt / equity | 0.09 | 0.11 | 47 |
| Cash conversion | 0.96 | 1.25 | 30 |
| Trailing P/E | 37.34 | 43.26 | 36 |
| P/B | 6.07 | 5.88 | 53 |
Questions
What is the P/E ratio of IPCA Laboratories Limited?
IPCA Laboratories Limited's trailing P/E is 37.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 29 May 2025 its P/E has ranged 33.1–54.2.
What were IPCA Laboratories Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, IPCA Laboratories Limited reported revenue of ₹2,788 cr and net profit of ₹402 cr (consolidated), filed with the exchange on 13 Aug 2026.
What is IPCA Laboratories Limited's ROE?
Return on equity is 19.9% based on the balance sheet dated 31 Mar 2026.
Does IPCA Laboratories Limited have debt?
Debt-to-equity is 0.09 on the balance sheet dated 31 Mar 2026.
What is IPCALAB's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, IPCALAB traded between ₹1,251.60 and ₹2,038.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.